Last Update 20 Jul 26
Fair value Increased 20%MYCR: Mixed Rating Shifts And Guidance Reset Will Shape Future Upside Potential
Analysts have raised their fair value estimate for Mycronic from SEK 260.25 to SEK 311.50, citing updated assumptions around revenue growth, profit margins, and a lower expected future P/E multiple, in the context of recent mixed broker views including a SEK 385 target from SEB Equities.
Analyst Commentary
Analyst views on Mycronic are mixed, with some taking a more constructive stance on the stock while others have turned more cautious. This split is reflected in recent rating changes and target prices, giving you a range of viewpoints on valuation, growth assumptions, and execution risk.
Bullish Takeaways
- Bullish analysts see enough support in Mycronic's outlook to justify an upgraded rating and a SEK 385 price target, which sits meaningfully above the current fair value estimate of SEK 311.50.
- The higher target price from bullish analysts suggests confidence that Mycronic can execute on its revenue and margin assumptions implied in current models.
- Supportive views often hinge on the idea that, even with a lower expected future P/E multiple baked into fair value work, Mycronic still offers upside if the company delivers on its operational plans.
- For investors, the bullish camp underscores the potential for the stock to trade closer to the upper end of valuation ranges used in recent research if execution stays on track.
Bearish Takeaways
- Bearish analysts have downgraded Mycronic, reflecting concerns that the current share price already factors in optimistic assumptions on growth and profitability.
- These more cautious views often point to execution risk, where any shortfall against revenue or margin expectations could put pressure on how much investors are willing to pay in terms of P/E.
- The downgrades highlight a view that the risk and reward balance has become less attractive, especially if the stock trades closer to the higher target levels cited by bullish analysts.
- For readers, the bearish stance serves as a reminder to stress test their own expectations for Mycronic against more conservative scenarios for growth, margins, and valuation multiples.
What’s in the News for Mycronic
- Mycronic raised its 2026 revenue guidance, with the Board revising expected net sales from SEK 8.25 billion to SEK 8.75 billion. (Source: Corporate guidance)
- Mycronic later adjusted its 2026 revenue guidance again, with the Board revising expected net sales from SEK 8.75 billion to SEK 9.25 billion. (Source: Corporate guidance)
- The company received an order for an SLX mask writer from an existing customer in Asia, valued in the range of US$5 million to US$7 million, with delivery planned for the third quarter of 2026. (Source: Client announcement)
- Mycronic also received an SLX mask writer order from a new customer in Europe, valued in the range of US$6 million to US$8 million, with delivery planned for the third quarter of 2026. (Source: Client announcement)
Valuation Changes
- Fair Value: The fair value estimate for Mycronic has moved from SEK 260.25 to SEK 311.50, indicating a higher assessed valuation for the stock.
- Discount Rate: The discount rate used in the model has fallen slightly from 6.98% to 6.83%, which can increase the present value of future cash flows.
- Revenue Growth: The assumed revenue growth rate has risen from 10.59% to 13.26%, reflecting a higher projected top line growth profile in SEK terms.
- Net Profit Margin: The modelled net profit margin has increased from 17.84% to 23.20%, implying a stronger earnings contribution for each SEK of revenue.
- Future P/E: The assumed future P/E multiple has declined from 31.03x to 25.40x, signalling a more cautious stance on how much investors might pay for Mycronic's earnings over time.
Key Takeaways
- Mycronic's acquisitions and new technology launches are bolstering revenue and market position, particularly in the Global Technologies and display industries.
- Strategic geographic expansion and increased R&D investments indicate potential for long-term revenue growth and market diversification.
- The combination of tariffs, demand weakness, and currency fluctuations is leading to declining revenues and earnings instability in Mycronic's High Flex division.
Catalysts
About Mycronic- Develops, manufactures, and sells production equipment for electronics industry in Sweden, rest of Europe, the United States, other Americas, China, South Korea, rest of Asia, and internationally.
- Mycronic's recent acquisitions, such as Hprobe and RoBAT, are expected to expand its offerings in the Global Technologies division with unique technologies for testing MRAM and PCBs, potentially leading to increased revenue and strengthened market position.
- The successful launch of the Prexision 8000 Evo, a high-end machine for mask writing in the display industry, confirms alignment with industry needs, and its reception may drive future order volumes, positively impacting revenue and earnings.
- Strong growth in the company's High Volume division, particularly in the Chinese domestic market, suggests potential for increased sales and revenue growth, supported by a robust order backlog.
- Continued expansion into new regions, like Southeast Asia, for High Volume production indicates strategic geographic diversification, which may enhance revenue stability and long-term growth prospects.
- Increased R&D investments in Pattern Generators, with a focus on new product development and market opportunities such as inspection and quality control, could support long-term revenue growth and competitive positioning.
Mycronic Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Mycronic's revenue will grow by 13.3% annually over the next 3 years.
- Analysts assume that profit margins will increase from 20.1% today to 23.2% in 3 years time.
- Analysts expect earnings to reach SEK 2.9 billion (and earnings per share of SEK 12.89) by about July 2029, up from SEK 1.7 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting SEK3.3 billion in earnings, and the most bearish expecting SEK2.2 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.5x on those 2029 earnings, down from 38.1x today. This future PE is greater than the current PE for the GB Electronic industry at 24.0x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.83%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The impact of new tariffs in the U.S. has caused delays in deliveries within the High Flex division, negatively impacting quarterly earnings by SEK 15 million and potentially affecting future revenues due to hesitation in investments.
- There is noted weakness in demand within the High Flex division, particularly in Europe, leading to a decrease in order intake by 12% and negatively impacting net sales and earnings.
- The financial outlook is uncertain due to fluctuations in exchange rates and the potential indirect effects of tariffs, which could lead to lower projected sales and impact both revenue and net margins.
- Uncertainty in the investment climate and potential hesitation to invest due to market conditions and currency fluctuations could lead to volatility in order intake and revenues, especially in divisions with shorter lead times like High Flex.
- Dependency on a limited number of customers in some divisions, such as Die Bonding in the Global Technologies division, can lead to fluctuating order intake, impacting revenue stability and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of SEK311.5 for Mycronic based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK385.0, and the most bearish reporting a price target of just SEK211.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK12.6 billion, earnings will come to SEK2.9 billion, and it would be trading on a PE ratio of 25.5x, assuming you use a discount rate of 6.8%.
- Given the current share price of SEK338.2, the analyst price target of SEK311.5 is 8.6% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Mycronic?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.